| ZFIN ID: ZDB-EXP-220817-3 |
Experiment Conditions Description: chemical treatment by injection: ManNAz-DBCO-Pam3CSK4
| chemical treatment by injection: ManNAz-DBCO-Pam3CSK4 |
|---|
| Name: | chemical treatment by injection |
|---|---|
| Synonyms: | |
| Definition: | Chemical treatment in which the chemical is injected into the zebrafish. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000237] |
| Name: | ManNAz-DBCO-Pam3CSK4 |
|---|---|
| Synonyms: | 5-{[8-(3-{[(2R)-6-amino-2-{[(2R)-6-amino-2-{[(2R)-6-amino-2-({S-[2,3-bis(hexadecanoyloxy)propyl]-N-hexadecanoyl-D-cysteinyl-D-seryl-D-lysyl}amino)hexanoyl]amino}hexanoyl]amino}hexanoyl]amino}propanoyl)-3a,8,9,13b-tetrahydro-3H-dibenzo[b,f][1,2,3]triazolo[ |
| Definition: | A carbohydrate derivative formed from a tetra-acetyl-N-azidoacetylmannosamine (AC4ManNAz) linked through a dibenzylcyclooctyl group (DBCO) to the triacylipopeptide N-palmitoyl-S-[2,3-bis(palmitoyloxy)propyl]-Cys-Ser-Lys-Lys-Lys-Lys (Pam3CSK4; CHEBI:134411). Commonly abbreviated to MDP, it has been developed as an artificial neoantigen on tumour cells to enhance tumour immunogenicity, able to significantly improve the response and the clinical outcome of immune checkpoint inhibitors (ICIs). |
| Ontology: | ChEBI [CHEBI:183049] ( EBI ) |
| Publication: | Rajan et al., 2021 |
|---|